MorphoSys Announces Presentation of Preclinical Data on MOR202 and MOR208 at 2012 American Society of Hematology Annual Meeting
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Announces Presentation of Preclinical Data on MOR202 and MOR208 at
2012 American Society of Hematology Annual Meeting
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today the
publication of additional preclinical data on its two proprietary cancer
programs MOR208 and MOR202 in the online issue of the peer-reviewed medical
journal BLOOD. The data sets further underline the potential of both compounds
to result in new treatment options for various forms of blood-borne cancer. Full
data will be presented at the 2012 American Society of Hematology (ASH) annual
meeting on December 8-11, 2012 in Atlanta.
MOR208, an anti-CD19 antibody with a proprietary modification to the Fc portion,
has successfully concluded a phase 1/2a clinical trial in chronic lymphocytic
leukemia (CLL). The program is on track to enter clinical development in non-
Hodgkin's lymphoma (NHL) and acute lymphoblastic leukemia (ALL). The preclinical
in vitro study to be presented at ASH examined MOR208's potential to trigger
antibody-dependent cell-mediated cytotoxicity (ADCC) relative to a native non-
engineered anti-CD19 antibody. In the study, MOR208 showed significantly
enhanced cytotoxicity triggering killing of cancer cells derived from both
pediatric and adult patients with ALL. MOR208 was twice as effective as the non-
engineered antibody and required lower antibody levels and lower presence of
effector cells.
MOR202, an anti-CD38 HuCAL antibody, is currently being tested in a phase 1/2a
study in patients with relapsed or refractory multiple myeloma (MM). Having
previously identified ADCC as an effector mechanism of MOR202, the preclinical
data to be presented at ASH demonstrate the antibody's capability to induce
killing of MM patient cells via antibody dependent cellular phagocytosis (ADCP)
as an additional potent mechanism.
"These findings for our proprietary cancer programs MOR202 and MOR208 are very
encouraging and highlight the significant potential of both candidates. MOR208
may represent a promising approach for treatment of pediatric and adult ALL,"
commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "For
MOR202, the additional effector mechanism bodes well for future clinical
development in multiple myeloma."
In total, MorphoSys currently has four proprietary clinical programs ongoing,
namely MOR208 and MOR202, as well as MOR103, a fully human HuCAL antibody
directed against GM-CSF (granulocyte macrophage-colony stimulating factor), that
is being developed in rheumatoid arthritis and multiple sclerosis.
The full abstracts are available on
https://ash.confex.com/ash/2012/webprogram/start.html
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare. The
Company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
applications.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®
and 100 billion high potentials® are registered trademarks of MorphoSys AG
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary
of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
investors(at)morphosys.com
Media Release:
http://hugin.info/130295/R/1655063/534742.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1655063]
Unternehmensinformation / Kurzprofil:
Datum: 05.11.2012 - 16:38 Uhr
Sprache: Deutsch
News-ID 199677
Anzahl Zeichen: 6015
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 158 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Announces Presentation of Preclinical Data on MOR202 and MOR208 at 2012 American Society of Hematology Annual Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
